Partnership plans trial of antidote to Factor Xa inhibitors

02/6/2013 | American City Business Journals

Portola Pharmaceuticals has entered a partnership with Bayer HealthCare and Johnson & Johnson's Janssen Pharmaceuticals to support a midstage clinical trial of PRT-4445, a reversal agent for anticoagulant Factor Xa inhibitor drugs. The study will involve patients treated with rivaroxaban.

View Full Article in:

American City Business Journals

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regulatory Compliance Specialist
MJHS
Brooklyn, NY
Director of Utilization Management
Meridian Health Plan
Chicago, IL
Senior Manager, Healthcare Reform
Avalere Health
Washington, DC
Regulatory Senior Managing/Principal Engineer/Scientist
Exponent
Menlo Park, CA
Director of Claims
Meridian Health Plan
Detroit, MI